Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02967458 · ClinicalTrials.gov registry record · Phase 2
Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study
A Phase 2 study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT02967458 is a Phase 2 study that has completed, run by Thomas Jefferson University. The registered enrollment target is 55 participants.
The verdict
NCT02967458, a Phase 2 study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a phase II single center study using contrast-enhanced ultrasound to identify aggressive forms of prostate cancer with subharmonic imaging. The following are the study objectives: 1. To implement subharmonic imaging technology on a transrectal probe suitable for prostate imaging and biopsy 2. To demonstrate visualization of prostatic vascularity using subharmonic contrast-enhanced imaging. 3. To provide a preliminary estimate of the diagnostic accuracy of contrast-enhanced subharmonic imaging for detection of clinically significant PCa. The study will include 50 subjects who are scheduled for prostate biopsy. Each subject will receive an intravenous infusion of microbubble contrast material immediately prior to a prostate biopsy procedure. The study will demonstrate whether subharmonic imaging with a microbubble contrast agent allows for detection of clinically significant prostate cancer.
Interventions
- DRUG Perflutren Lipid Microsphere Intravenous Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-02-01 |
| Est. Completion | 2018-09-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02967458
The ClinicalTrials.gov registry entry for NCT02967458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perflutren Lipid Microsphere Intravenous Suspension is the first listed.
NCT02967458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02967458 about?
NCT02967458 is a clinical study titled "Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study". This is a phase II single center study using contrast-enhanced ultrasound to identify aggressive forms of prostate cancer with subharmonic imaging. The following are the study objectives: 1. To implement subharmonic imaging technology on a transrectal probe suitable for prostate imaging and biopsy...
What is the current status of trial NCT02967458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2017-02-01. Estimated completion is 2018-09-20.
What interventions are being tested in trial NCT02967458?
The interventions under investigation include: Perflutren Lipid Microsphere Intravenous Suspension (DRUG).
Who is sponsoring clinical trial NCT02967458?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.